

# Form C

## ANNUAL STATISTICS OF PRODUCTION, MANUFACTURE, CONSUMPTION, STOCKS AND SEIZURES OF NARCOTIC DRUGS

Single Convention on Narcotic Drugs, 1961: Articles 1, 2, 13, 20 and 27.

Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961: Articles 1 and 10.

COUNTRY/TERRITORY: _____	DATE: _____
COMPETENT OFFICE: _____	
RESPONSIBLE OFFICER'S NAME: _____	
TELEPHONE NUMBER: _____	E-MAIL: _____
TITLE/FUNCTION: _____	SIGNATURE: _____
Statistics related to the calendar year _____	

### REMARKS

The Form should be completed as soon as possible and not later than 30 June of the year following the year to which the statistical data relate

and sent to:

**INTERNATIONAL NARCOTICS CONTROL BOARD**

**Vienna International Centre**

**P. O. Box 500, A-1400 Vienna, Austria**

**Telephone: (+43-1) 26060-4277 Facsimile: (+43-1) 26060 5867**

**Telegraphic address: UNATIONS VIENNA Telex: 135612 uno a**

**E-mail: [secretariat@incb.org](mailto:secretariat@incb.org) Website: <http://www.incb.org/>**

## INSTRUCTIONS

PLEASE READ CAREFULLY AND COMPLETE THE FORM IN A CLEAR MANNER

### General:

1. This form is divided into **four** parts:  
Part I: statistical data on manufacture, consumption, utilization and stocks of narcotic drugs.  
Part II: statistical data on the manufacture of narcotic drugs.  
Part III: statistical data on the licit cultivation of the opium poppy and the licit production of cannabis, coca leaf and opium.  
Part IV: statistical data on seizures of narcotic drugs.
2. In order to ensure the accurate completion of this form, the definitions given below, in accordance with the provisions of article 1 of the Single Convention on Narcotic Drugs, 1961, should be borne in mind:
  - a. **Consumption** is the action of supplying a narcotic drug to any person or enterprise for retail distribution, medical use or scientific research.
  - b. **Drug** designates any substance included in Schedules I and II of the Convention, whether natural or synthetic, and subject to specific control measures under the Convention.
  - c. **Manufacture** is any process, other than production (see definition below), by which drugs may be obtained, including the refining and transformation of one drug into another drug.
  - d. **Preparation** is a mixture, solid or liquid, containing a drug and subject to the same control measures as the drug it contains. It should be noted, however, that preparations listed in Schedule III of the Single Convention are exempted from some control measures.
  - e. **Production** is the separation of opium, coca leaves, cannabis and cannabis resin from the plants from which they are obtained.
  - f. **Stocks** are the amounts of drugs held in a country/territory for domestic consumption, manufacture of other drugs or exports.
  - g. **Special stocks** are the amounts of drugs held by the Government of a country/territory, for special government purposes and to meet exceptional circumstances.
3. All drugs and preparations are listed in the *List of Narcotic Drugs under International Control* (Yellow List), a supplement to the statistical forms on narcotic drugs, distributed to Governments on a yearly basis. Poppy straw produced from varieties of opium poppy rich in morphine is referred to as **poppy straw (M)**. Poppy straw produced from varieties of opium poppy rich in thebaine is referred to as **poppy straw (T)**. Concentrate of poppy straw containing morphine as the main alkaloid is referred to as **concentrate of poppy straw (M)**. Concentrate of poppy straw containing thebaine as the main alkaloid is referred to as **concentrate of poppy straw (T)**. Concentrate of poppy straw containing oripavine as the main alkaloid is referred to as **concentrate of poppy straw (O)**.
4. Figures included in this form should be **expressed in terms of the pure anhydrous drug content** of the respective quantities of the crude drug, refined drug, base, salt or preparation, other than those listed in Schedule III of the Single Convention, being accounted for. Furthermore, all figures reported in this form should reflect the **net quantity** involved, that is, not including the weight of packages or containers (cases, boxes, wrappers, bottles, tubes, ampoules, etc.) and all figures should be entered in kilograms and grams, or in grams and milligrams, **without decimal points or commas**. Tables showing the pure drug content of bases, esters, ethers and salts are provided in the Yellow List (Part 4, Table 1).
5. In the case of extracts and tinctures of opium, coca leaf and cannabis, the relevant criteria and conversion factors are included in the Yellow List (Part 4, Table 2).
6. **With respect to concentrate of poppy straw and poppy straw, the gross weights of the materials and, in addition, the approximate quantities of AMA (anhydrous morphine alkaloid), ACA (anhydrous codeine alkaloid), ATA (anhydrous thebaine alkaloid) and AOA (anhydrous oripavine alkaloid) contained in these materials, are to be reported.**

**Part I:**

7. This part is divided into two sections. **Part I.a** is to be filled out by **all Governments**, even if no manufacture of narcotic drugs takes place. In this case the respective space in Column I should be left blank, but data on consumption and stocks should be furnished in detail. **Part I.b** is reserved for countries which utilize or keep stocks of concentrate of poppy straw.
8. For practical purposes, drugs listed in this part have been subdivided into two groups. First, there are the substances which should be reported to the Board in kilograms and/or grams, immediately after those which are to be reported in grams and/or milligrams. In both groups, substances appear in alphabetical order.
9. Parts I.a and I.b are organized in six numbered columns:
- Column 1:** should be used to enter data on the quantities of drugs manufactured during the year in question. It should be noted that, for each substance, the data entered in this column should reflect an aggregate figure of the data entered in Column 4 of Part II (see instructions below).
- Column 2:** should be used to enter data on the consumption of the respective narcotic drug during the year in question.
- Column 3:** should be used to enter data on the quantities of drugs used in the manufacture of Schedule III preparations. It is, therefore, not applicable to substances not listed in Schedule III.
- Column 4:** should be used to enter data on stocks held as at 31 December of the year in question.
- Column 5:** should be used to indicate the amounts procured for and/or withdrawn from special stocks. Whether the amount has been procured (P) or withdrawn (W) should be clearly indicated by adding the respective initial next to each figure, or by indicating it in the space provided for remarks on the cover page.
- Column 6:** should be used to enter data on losses and destructions during the process of manufacture and wholesale distribution of narcotic drugs. Losses and destructions should include those occurring during manufacture of raw materials, manufacture of preparations and during industrial research and development. Data referring to the destruction of obsolete materials or preparations should also be included. Comprehensive guidelines on reporting under this column can be found on the INCB website ([www.incb.org/incb/narcotic\\_drugs.html](http://www.incb.org/incb/narcotic_drugs.html)).

**Part II:**

10. This part is reserved for countries which manufacture narcotic drugs. It is organized in four numbered columns:
- Column 1:** contains a listing of the most often manufactured narcotic drugs and, at the bottom, provides space in case parties wished to add other narcotic drugs, as may be required.
- Column 2:** is to be used to enter the quantities of substances in Column 1 used for the manufacture of substances listed in Column 3, or of other drugs as may be the case.
- Column 3:** contains a listing of the substances most often manufactured from substances listed in Column 1 and provides space in case parties wished to add other narcotic drugs they may manufacture.
- Column 4:** is to be used to enter the quantities of substances in Column 3 manufactured from substances listed in Column 1, or of other drugs as may be the case.

**Part III:**

11. This part is divided into two sections:
- Part III.a.** is reserved for countries which authorize the cultivation of the opium poppy. It contains two columns for the entry of statistical data; **Column 1** should be used for data on cultivation area in hectares, including the total area sown and the total area actually harvested; **Column 2** is to be used for the total quantity of the substances listed in the last column to the right (opium and/or poppy straw), obtained from the total area harvested. Quantities entered in Column 2 should all be in kilograms.
- Part III.b.** is reserved for countries which authorize the production of cannabis and/or coca leaf. As there is no treaty requirement for parties to furnish the Board with statistical data on cultivation areas for the cannabis plant or the coca bush, **Column 1** is not applicable to these substances. However, statistical data on the quantities of cannabis and coca leaf produced in a country/territory should be furnished in **Column 2**.

**Part IV:**

12. This part is divided into two sections. It is to be filled out by **all Governments**, whenever narcotic drugs have been seized, destroyed, used for licit purposes and/or taken over by Governments for special purposes during the year in question. Quantities pending disposal should also be indicated.

**ADDITIONAL REMARK**

When completing this form, it should be borne in mind that, although the quantities of drugs used in the manufacture of preparations in Schedule III of the Single Convention should be furnished to the Board, the actual quantities of Schedule III preparations consumed, held in stocks, procured for and withdrawn from special stocks, seized or disposed of NEED NOT be furnished to the Board and SHOULD NOT be added to the quantities of drugs reported as such. If Parties, however, deem it appropriate to furnish statistical data on Schedule III preparations, this should be clearly indicated in the space for remarks provided on the cover page.

**PART I.a**  
**(FOR ALL COUNTRIES)**

1		Narcotic drug	2		3		4		5			6	
Quantity manufactured			Quantity consumed		Quantity used for the manufacture of Schedule III preparations		Quantity held in stocks as at 31 December		Quantity procured (P) for or withdrawn (W) from special stocks			Quantity lost or destroyed *	
Kilograms	Grams		Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	P/W	Kilograms	Grams
		Alphaprodine											
		Anileridine											
		Bezitramide											
		Cannabis											
		Cannabis resin											
		Coca leaf											
		Cocaine											
		Codeine											
		Dextromoramide											
		Dextropropoxyphene											
		Difenoxin											
		Dihydrocodeine											
		Diphenoxylate											
		Dipipanone											
		Ethylmorphine											
		Etorphine											
		Heroin											
		Hydrocodone											
		Hydromorphone											
		Ketobemidone											
		Levorphanol											

\* See the instructions on Page 3, Paragraph 9, under Column 6.

**PART I.a**

(FOR ALL COUNTRIES)

1		Narcotic drug	2		3		4		5			6	
Quantity manufactured			Quantity consumed		Quantity used for the manufacture of Schedule III preparations		Quantity held in stocks as at 31 December		Quantity procured (P) for or withdrawn (W) from special stocks			Quantity lost or destroyed *	
Kilograms	Grams		Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	P/W	Kilograms	Grams
		<b>Methadone</b>											
		<b>Morphine</b>											
		<b>Nicomorphine</b>											
		<b>Normethadone</b>											
		<b>Opium</b>											
		<b>Oripavine</b>											
		<b>Oxycodone</b>											
		<b>Oxymorphone</b>											
		<b>Pethidine</b>											
		<b>Phenoperidine</b>											
		<b>Pholcodine</b>											
		<b>Thebacon</b>											
		<b>Thebaine</b>											
		<b>Tilidine</b>											
		<b>Trimeperidine</b>											
Kilograms	Grams		Grams	Milligrams	Grams	Milligrams	Grams	Milligrams	Grams	Milligrams	P/W	Grams	Milligrams
		<b>Alfentanil</b>											
		<b>Fentanyl</b>											
		<b>Piritramide</b>											
		<b>Remifentanil</b>											
		<b>Sufentanil</b>											

\* See the instructions on Page 3, Paragraph 9, under Column 6.

**PART I.b**  
**(ONLY FOR COUNTRIES WHICH UTILIZE OR KEEP STOCKS OF CONCENTRATE OF POPPY STRAW)**

1		Narcotic drug	2		3		4		5			6	
Quantity manufactured			Quantity consumed		Quantity used for the manufacture of Schedule III preparations		Quantity held in stocks as at 31 December		Quantity procured (P) for or withdrawn (W) from special stocks			Quantity lost or destroyed *	
Kilograms	Grams		Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	P/W	Kilograms	Grams
**		<b>Concentrate of poppy straw (M)</b>	**				**		**			**	
		AMA	***				***		***			***	
		ACA	***				***		***			***	
		ATA	***				***		***			***	
		AOA	***				***		***			***	
**		<b>Concentrate of poppy straw (T)</b>	**				**		**			**	
		ATA	***				***		***			***	
		AMA	***				***		***			***	
		ACA	***				***		***			***	
		AOA	***				***		***			***	
**		<b>Concentrate of poppy straw (O)</b>	**				**		**			**	
		AOA	***				***		***			***	
		AMA	***				***		***			***	
		ACA	***				***		***			***	
		ATA	***				***		***			***	

\* See the instructions on Page 3, Paragraph 9, under Column 6.

\*\* Quantities to be expressed in gross weight.

\*\*\* Approximate quantity of the respective anhydrous alkaloid contained in concentrate of poppy straw.

**PART II**  
(ONLY FOR COUNTRIES WHICH UTILIZE NARCOTIC DRUGS FOR MANUFACTURE OF OTHER SUBSTANCES)

1	2		3		4	
Substance used	Quantity used		Substance obtained		Quantity obtained	
	Kilograms	Grams			Kilograms	Grams
<b>Opium</b>			<b>Morphine</b>			
			<b>Codeine</b>			
			<b>Thebaine</b>			
<b>Poppy straw (M)</b>			<i>Concentrate of poppy straw (M)</i>		*	
			AMA (kg)	**		
			ACA (kg)	**		
			ATA (kg)	**		
			AOA (kg)	**		
			<b>Morphine</b>			
			<b>Codeine</b>			
			<b>Thebaine</b>			
			<b>Oripavine</b>			
<b>Poppy straw (T)</b>			<i>Concentrate of poppy straw (T)</i>		*	
			ATA (kg)	**		
			AMA (kg)	**		
			ACA (kg)	**		
			AOA (kg)	**		
			<i>Concentrate of poppy straw (O)</i>		*	
			AOA (kg)	**		
			AMA (kg)	**		
			ACA (kg)	**		
			ATA (kg)	**		
<i>Papaver bracteatum</i> <sup>1</sup>			<b>Thebaine</b>			
<i>Concentrate of poppy straw (M)</i>	*					
AMA (kg)			<b>Morphine</b>			
ACA (kg)			<b>Codeine</b>			
ATA (kg)			<b>Thebaine</b>			
AOA (kg)			<b>Oripavine</b>			
<i>Concentrate of poppy straw (T)</i>	*					
ATA (kg)			<b>Thebaine</b>			
AMA (kg)			<b>Morphine</b>			
ACA (kg)			<b>Codeine</b>			
AOA (kg)			<b>Oripavine</b>			
<i>Concentrate of poppy straw (O)</i>	*					
AOA (kg)			<b>Oripavine</b>			
AMA (kg)			<b>Morphine</b>			
ACA (kg)			<b>Codeine</b>			
ATA (kg)			<b>Thebaine</b>			
<i>Residual water containing alkaloids (please specify origin)</i>			<b>Codeine</b>			
			<b>Morphine</b>			
			<b>Oripavine</b>			
			<b>Thebaine</b>			

<sup>1</sup> Economic and Social Council (ECOSOC) resolution 1982/12 recommends Governments to refrain from undertaking the commercial cultivation of *Papaver bracteatum*.

\* Quantities to be expressed in gross weight.

\*\* Approximate quantity of the respective anhydrous alkaloid contained in concentrate of poppy straw.

**PART II**  
**(ONLY FOR COUNTRIES WHICH UTILIZE NARCOTIC DRUGS FOR MANUFACTURE OF OTHER SUBSTANCES)**

1	2		3	4	
Substance used	Quantity used		Substance obtained	Quantity obtained	
	Kilograms	Grams		Kilograms	Grams
Morphine			Codeine		
			Ethylmorphine		
			Heroin		
			Hydromorphone		
			Pholcodine		
			Apomorphine		
			Nalorphine		
Oripavine			Hydromorphone		
			Oxymorphone		
			Thebaine		
Thebaine			Codeine		
			Dihydrocodeine		
			Hydrocodone		
			Oxycodone		
			Thebacon		
			Buprenorphine		
			Nalbuphine		
			Naloxone		
Codeine			Dihydrocodeine		
			Hydrocodone		
Oxycodone			Oxymorphone		
			Naloxone		
			Naltrexone		
Coca leaf			Cocaine		
			Coca paste		
			Ecgonine		
Coca paste			Cocaine		
Ecgonine			Cocaine		
Hydrocodone			Dihydrocodeine		
			Thebaine		
Methadone intermediate			Methadone		
Pethidine intermediate A			Pethidine intermediate B		
Pethidine intermediate B			Pethidine intermediate C		
Pethidine intermediate C			Pethidine		
Racemoramide			Dextromoramide		
			Levomoramide		

**PART III.a**  
**(ONLY FOR COUNTRIES WHICH AUTHORIZE CULTIVATION OF OPIUM POPPY AND/OR PRODUCTION OF OPIUM)**

Cultivation of the opium poppy	1		2	
	Area cultivated (Hectares)		Quantity produced (Kilograms)	
	Sown	Harvested	Opium	Poppy straw <sup>2</sup>
1. For the production of <b>opium</b>				
2 a. For the production of <b>poppy straw (M)</b> (for manufacture of narcotic drugs)				
2 b. For the production of <b>poppy straw (T)</b> (for manufacture of narcotic drugs)				
3. For purposes other than the production or manufacture of narcotic drugs				

**PART III.b**  
**(ONLY FOR COUNTRIES WHICH AUTHORIZE PRODUCTION OF CANNABIS AND/OR COCA LEAF)**

Production of cannabis	Kilograms
Production of coca leaf	Kilograms

<sup>2</sup> Requested on a voluntary basis, pursuant to ECOSOC resolution 1978/12 of 5 May 1978 and to General Assembly resolution 33/168 of 20 December 1978.

**PART IV  
SEIZURES OF NARCOTIC DRUGS  
(FOR ALL COUNTRIES)**

<b>A. Seizures of narcotic drugs (excluding pharmaceutical products)<sup>3</sup></b>										
Substance	1		2		3		4		5	
	Quantity seized		Disposal of seized quantities (including those seized in previous years)						Seized quantity not disposed of pending a decision	
			Quantity destroyed		Quantity used for licit purposes <sup>4</sup>		Quantity taken over by Government for special purposes			
	Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	Kilograms	Grams	Kilograms	Grams
<b>Cannabis</b>										
<b>Cannabis resin</b>										
<b>Coca leaf</b>										
<b>Coca paste</b>										
<b>Cocaine</b>										
<b>Heroin</b>										
<b>Morphine</b>										
<b>Opium</b>										
<b>Others<sup>5</sup></b>										

<sup>3</sup> Quantities to be expressed in gross weight.

<sup>4</sup> Governments that release seized drugs for licit medical and scientific purposes should, in addition to the gross weight of the drug released, also report their pure anhydrous drug content in order to facilitate the monitoring by INCB of the consumption and/or utilization of these drugs. This information may be included in the space under "Remarks" on page 1 of the Form C.

<sup>5</sup> Any other narcotic drug, including synthetic narcotic drugs such as fentanyl analogues.

<b>B. Seizures of pharmaceutical products containing narcotic drugs</b>											
Substance	Pharmaceutical form and content of active ingredient per unit										
	1 Ampoules		2 Capsules		3 Patches		4 Tablets		5 Other forms		
	Number of units	Content per unit (mg)	Number of units	Content per unit (mg)	Number of units	Content per unit (mg)	Number of units	Content per unit (mg)	Kind	Number of units	Content per unit (mg)
<b>Codeine</b>											
<b>Fentanyl</b>											
<b>Methadone</b>											
<b>Morphine</b>											
<b>Oxycodone</b>											
<b>Pethidine</b>											
<b>Others<sup>6</sup></b>											

<sup>6</sup> Any other pharmaceutical product containing narcotic drugs such as dihydrocodeine, dextropropoxyphene, hydrocodone, hydromorphone, trimeperidine, etc.